Meeting: ESMO | DocGuide

Auto-generated: May 16 2012 01:44 PM GMT-8

Meeting: ESMO

30

Stars

Source: DGNews | Posted 1 year ago

First-Line FOLFIRI Improves Time to Treatment Failure Versus Standard Therapy for Advanced Gastric Cancer

Tags:

Read/Add Comments

36

Stars

Source: DGNews | Posted 1 year ago

Adding Afatinib to Best Supportive Care Improves Progression-Free Survival in Patients With Advanced NSCLC

Tags:

Read/Add Comments

33

Stars

Source: DGNews | Posted 1 year ago

Adding Cediranib to FOLFOX/XELOX Improves Progression-Free Survival in Patients With Metastatic Colorectal Cancer

Tags:

Read/Add Comments

26

Stars

Source: DGNews | Posted 1 year ago

Adding Bevacizumab to Standard Chemo Improves Progression-Free Survival in Patients With Gynaecological Cancers

Tags:

Read/Add Comments

27

Stars

Source: DGNews | Posted 1 year ago

Adding Sorafenib to Gemcitabine/Cisplatin Improves Progression-Free Survival in Patients With Advanced NSCLC

Tags:

Read/Add Comments

26

Stars

Source: DGNews | Posted 1 year ago

Carboplatin Plus Pegylated Liposomal Doxorubicin Not Superior to Carboplatin Plus Paclitaxel in Advanced Ovarian Cancer

Tags:

Read/Add Comments

31

Stars

Source: DGNews | Posted 1 year ago

Trial of Patupilone Fails to Meet Primary Endpoint but Shows Other Benefits for Gynaecological Cancers

Tags:

Read/Add Comments

64

Stars

Source: DGNews | Posted 1 year ago

Abiraterone Acetate Plus Prednisone Improves Overall Survival in Some Prostate Cancers

Tags:

Read/Add Comments

28

Stars

Source: DGNews | Posted 1 year ago

Maintenance Gefitinib Prolongs Progression-Free Survival, but Not Overall Survival in Patients With NSCLC

Tags:

Read/Add Comments

54

Stars

Source: DGNews | Posted 1 year ago

Adding Iniparib to Gemcitabine/Carboplatin Improves Outcomes in Metastatic Triple-Negative Breast Cancer

Tags:

Read/Add Comments

Terms of Use | Privacy Policy

© All Content Copyright 1995 - 2012 Doctor's Guide Publishing Limited. All Rights Reserved.